Ms. Dianna Zhang joined JunHe in 2016 and specializes in a range of capital market related practices. Her expertise covers fund formation, private equity investment and financing, mergers and acquisitions, restructuring, overseas listings, and corporate governance. Ms. Zhang has advised clients across diverse sectors including life sciences and healthcare, new energy vehicles, artificial intelligence, semiconductors and smart manufacturing, new consumer brands, and media.

With experience in fund formation and private equity transactions, Ms. Zhang has represented leading PE/VC funds such as Sequoia Capital, CDH Investments, Highlight Capital, BioTrack Capital, Fengshion Capital, and Sunrise Capital. She has assisted numerous PE/VC funds in establishing multiple RMB-denominated and USD-denominated funds. Her notable private equity deals include representing 4Paradigm in a multi-tranche financing deal, representing Face++ in its financing, representing Uxin Group in a multi-tranche financing deal, advising Sequoia Capital in its investment in a medical nursing center and advising Yonghua Capital in its investment in a gene testing company.

Ms. Zhang's landmark IPO projects in overseas listings include XPeng Inc.'s NYSE listing and subsequent dual-primary listing on HKEX, 4Paradigm's HKEX IPO, Uxin Group's NASDAQ listing, and Mobvista's HKEX listing. Her institutional clients include major investment banks such as Goldman Sachs, Bank of America, J.P. Morgan, Citigroup, CICC and UBS.